These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 16224447)
41. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Salzberg M; Thurlimann B; Bonnefois H; Fink D; Rochlitz C; von Moos R; Senn H Oncology; 2005; 68(4-6):293-8. PubMed ID: 16020955 [TBL] [Abstract][Full Text] [Related]
42. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799 [TBL] [Abstract][Full Text] [Related]
43. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Ramirez PT; Schmeler KM; Milam MR; Slomovitz BM; Smith JA; Kavanagh JJ; Deavers M; Levenback C; Coleman RL; Gershenson DM Gynecol Oncol; 2008 Jul; 110(1):56-9. PubMed ID: 18457865 [TBL] [Abstract][Full Text] [Related]
44. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Covens A; Blessing J; Bender D; Mannel R; Morgan M; Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022 [TBL] [Abstract][Full Text] [Related]
45. Chemotherapy in epithelial ovarian cancer. Wang J; Li AJ; Karlan BY Curr Womens Health Rep; 2002 Feb; 2(1):20-6. PubMed ID: 12112979 [TBL] [Abstract][Full Text] [Related]
46. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349 [TBL] [Abstract][Full Text] [Related]
47. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988 [TBL] [Abstract][Full Text] [Related]
49. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Harter P; Hilpert F; Mahner S; Heitz F; Pfisterer J; du Bois A Expert Rev Anticancer Ther; 2010 Jan; 10(1):81-8. PubMed ID: 20014888 [TBL] [Abstract][Full Text] [Related]
50. Ovarian cancer as a chronic disease: a new treatment paradigm. Highlights of a roundtable discussion. Spriggs DR Cancer Control; 2001; 8(6 Suppl 1):5-7; discussion 8-18. PubMed ID: 11910332 [No Abstract] [Full Text] [Related]
52. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Lairson DR; Parikh RC; Cormier JN; Du XL Value Health; 2014; 17(1):34-42. PubMed ID: 24438715 [TBL] [Abstract][Full Text] [Related]
54. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655 [TBL] [Abstract][Full Text] [Related]